JP7656359B2 - アムホテリシンｂのハイブリッドアミド誘導体 - Google Patents

アムホテリシンｂのハイブリッドアミド誘導体 Download PDF

Info

Publication number
JP7656359B2
JP7656359B2 JP2023508551A JP2023508551A JP7656359B2 JP 7656359 B2 JP7656359 B2 JP 7656359B2 JP 2023508551 A JP2023508551 A JP 2023508551A JP 2023508551 A JP2023508551 A JP 2023508551A JP 7656359 B2 JP7656359 B2 JP 7656359B2
Authority
JP
Japan
Prior art keywords
compound
acid
compounds
amb
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023508551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537921A (ja
JPWO2022035752A5 (https=
JP2023537921A5 (https=
Inventor
ディー バーク，マーティン
マジ，アルン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2023537921A publication Critical patent/JP2023537921A/ja
Publication of JPWO2022035752A5 publication Critical patent/JPWO2022035752A5/ja
Publication of JP2023537921A5 publication Critical patent/JP2023537921A5/ja
Application granted granted Critical
Publication of JP7656359B2 publication Critical patent/JP7656359B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2023508551A 2020-08-10 2021-08-09 アムホテリシンｂのハイブリッドアミド誘導体 Active JP7656359B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063655P 2020-08-10 2020-08-10
US63/063,655 2020-08-10
US202163175771P 2021-04-16 2021-04-16
US63/175,771 2021-04-16
PCT/US2021/045205 WO2022035752A1 (en) 2020-08-10 2021-08-09 Hybrid amide derivatives of amphotericin b

Publications (4)

Publication Number Publication Date
JP2023537921A JP2023537921A (ja) 2023-09-06
JPWO2022035752A5 JPWO2022035752A5 (https=) 2024-08-16
JP2023537921A5 JP2023537921A5 (https=) 2024-08-16
JP7656359B2 true JP7656359B2 (ja) 2025-04-03

Family

ID=80247344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023508551A Active JP7656359B2 (ja) 2020-08-10 2021-08-09 アムホテリシンｂのハイブリッドアミド誘導体

Country Status (12)

Country Link
US (1) US20230357303A1 (https=)
EP (2) EP4696379A3 (https=)
JP (1) JP7656359B2 (https=)
KR (1) KR20230061405A (https=)
CN (1) CN116323632B (https=)
AU (1) AU2021325676A1 (https=)
CA (1) CA3190997A1 (https=)
ES (1) ES3061451T3 (https=)
IL (1) IL300441A (https=)
MX (1) MX2023001649A (https=)
PT (1) PT4192248T (https=)
WO (1) WO2022035752A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534382A (ja) 2000-05-31 2003-11-18 マイクロロジックス バイオテック，インコーポレイテッド ポリエンマクロライドの水溶性アミド誘導体ならびにそれらの調製および使用
WO2015190587A1 (ja) 2014-06-12 2015-12-17 塩野義製薬株式会社 ポリエンマクロライド誘導体
JP2017518982A (ja) 2014-05-16 2017-07-13 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 低減された毒性を有するアンホテリシンｂ誘導体
JP2018514522A (ja) 2015-04-15 2018-06-07 スファンガ セラピューティクス インコーポレイテッドＳｆｕｎｇａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アムホテリシンｂの誘導体
WO2020051465A1 (en) 2018-09-07 2020-03-12 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122086B1 (en) * 1979-04-09 1982-06-30 Politechnika Gdanska Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP4009985A4 (en) * 2019-08-08 2023-09-06 The Board Of Trustees Of The University Of Illinois HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534382A (ja) 2000-05-31 2003-11-18 マイクロロジックス バイオテック，インコーポレイテッド ポリエンマクロライドの水溶性アミド誘導体ならびにそれらの調製および使用
JP2017518982A (ja) 2014-05-16 2017-07-13 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 低減された毒性を有するアンホテリシンｂ誘導体
WO2015190587A1 (ja) 2014-06-12 2015-12-17 塩野義製薬株式会社 ポリエンマクロライド誘導体
JP2018514522A (ja) 2015-04-15 2018-06-07 スファンガ セラピューティクス インコーポレイテッドＳｆｕｎｇａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アムホテリシンｂの誘導体
WO2020051465A1 (en) 2018-09-07 2020-03-12 The Board Of Trustees Of The University Of Illinois Hybrid amphotericin b derivatives with reduced toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem.，2009年，52，189-196

Also Published As

Publication number Publication date
ES3061451T3 (en) 2026-04-01
JP2023537921A (ja) 2023-09-06
EP4192248B1 (en) 2025-12-03
IL300441A (en) 2023-04-01
WO2022035752A1 (en) 2022-02-17
EP4696379A3 (en) 2026-02-25
EP4192248A1 (en) 2023-06-14
CA3190997A1 (en) 2022-02-17
CN116323632B (zh) 2024-12-31
EP4192248A4 (en) 2024-12-04
AU2021325676A1 (en) 2023-03-30
MX2023001649A (es) 2023-04-24
US20230357303A1 (en) 2023-11-09
KR20230061405A (ko) 2023-05-08
CN116323632A (zh) 2023-06-23
EP4696379A2 (en) 2026-02-18
PT4192248T (pt) 2026-02-11

Similar Documents

Publication Publication Date Title
US11117920B2 (en) Amphotericin B derivatives with improved therapeutic index
US20230016424A1 (en) Hybrid amide derivatives of amphotericin b
CN118871113A (zh) 使用THR-β激动剂的肝脏病症的治疗
WO2014165676A1 (en) Amphotericin b derivative with reduced toxicity
US11198705B2 (en) Hybrid Amphotericin B derivatives with reduced toxicity
JP6726192B2 (ja) アムホテリシンｂの尿素誘導体の簡便な合成法
JP6796581B2 (ja) ミッシングタンパク質の小分子模倣体を用いた生理機能の回復
JP7656359B2 (ja) アムホテリシンｂのハイブリッドアミド誘導体
JP2022519685A (ja) カンナビジオール誘導体の製剤およびカンナビノイド受容体タイプ２（ｃｂ２）のモジュレーターとしてのその使用
AU2020329149A1 (en) Combination treatment of systemic fungal infections
US20230000891A1 (en) Hybrid amphotericin b derivatives with reduced toxicity
WO2016040779A1 (en) Urea derivatives of polyene macrolide antibiotics
NZ757647B2 (en) Amphotericin B derivatives with improved therapeutic index

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250314

R150 Certificate of patent or registration of utility model

Ref document number: 7656359

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150